As soon as direct STAT3 inhibitors reach the market, a rational combination for the pharmacologic treatment of cancer patients should include a STAT3 inhibitor to prevent and or reverse ADR and thereby increase the efficacy and duration of the therapeutic regimen. Here, STAT3 is linked to cancer.